BCPC Stock Analysis: Balchem | NASDAQ
Specialty Chemicals | NASDAQ, USA | Market Cap: 5.720m USD | 12M Return: 13.4% | US0576652004 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 32.3M
EPS Trend: 98.5%
Qual. Beats: 1
Rev. Trend: 95.9%
Qual. Beats: 2
Warnings
No concerns identified
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Balchem Corporation is a U.S.-based specialty ingredient manufacturer operating three core segments: Human Nutrition and Health (food and beverage ingredients such as spray-dried powders, microencapsulated nutrients, vitamin K2, and choline products), Animal Nutrition and Health (microencapsulated feed supplements, chelated minerals, methylsulfonylmethane, and choline chloride for livestock and companion animals), and Specialty Products (ethylene oxide and propylene oxide for sterilization and fumigation, plus chelated minerals for high-value crops). The company serves nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets globally, distributing through a direct sales force as well as independent distributors and sales agents. Founded in 1967 and headquartered in Montvale, New Jersey, Balchem trades on NASDAQ under the ticker BCPC.
Operating within the specialty chemicals sub-industry, Balchems business model centers on proprietary ingredient technologies-particularly microencapsulation and chelation-that enable controlled release and improved nutrient absorption. Diversification across human, animal, and industrial end-markets helps the company offset cyclical demand swings in any single application area.
- EPA tightens ethylene oxide rules on medical sterilization segment
- Functional food demand lifts vitamin K2 and choline sales
- Dairy industry health trends boost ruminant nutrition revenue
| Net Income: 164.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 1.04 > 1.0 |
| NWC/Revenue: 22.35% < 20% (prev 23.00%; Δ -0.65% < -1%) |
| CFO/TA 0.13 > 3% & CFO 219.6m > Net Income 164.4m |
| Net Debt (119.3m) to EBITDA (278.9m): 0.43 < 3 |
| Current Ratio: 2.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (32.2m) vs 12m ago -1.53% < -2% |
| Gross Margin: 36.29% > 18% (prev 35.80%; Δ 0.49% > 0.5%) |
| Asset Turnover: 64.53% > 50% (prev 58.75%; Δ 5.79% > 0%) |
| Interest Coverage Ratio: 24.31 > 6 (EBIT TTM 220.6m / Interest Expense TTM 9.07m) |
| A: 0.14 (Total Current Assets 388.4m - Total Current Liabilities 145.8m) / Total Assets 1.69b |
| B: 0.72 (Retained Earnings 1.21b / Total Assets 1.69b) |
| C: 0.13 (EBIT TTM 220.6m / Avg Total Assets 1.68b) |
| D: 3.39 (Book Value of Equity 1.30b / Total Liabilities 384.6m) |
| Altman-Z'' = 7.71 = AAA |
| DSRI: 0.99 (Receivables 149.0m/136.0m, Revenue 1.09b/985.9m) |
| GMI: 0.99 (GM 35.80% / 36.29%) |
| AQI: 0.97 (AQ_t 0.58 / AQ_t-1 0.60) |
| SGI: 1.10 (Revenue 1.09b / 985.9m) |
| TATA: -0.03 (NI 164.4m - CFO 219.6m) / TA 1.69b) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of August 12, 2026, the stock is trading at USD 179.01 with a total of 119,136 shares traded. Over the past week, the price has changed by +2.42%, over one month by +10.88%, over three months by +12.63% and over the past year by +13.36%.
Current recommended Stop Loss: 173.60 (which is 3% or 1.3 ATR below the current price).
Balchem has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy BCPC.
- StrongBuy: 0
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 209 | 16.8% |
P/E Trailing = 35.6012
P/E Forward = 31.746
P/S = 5.2675
P/B = 4.2778
P/EG = 3.9648
Revenue TTM = 1.09b USD
EBIT TTM = 220.6m USD
EBITDA TTM = 278.9m USD
Long Term Debt = 164.0m USD (from longTermDebt, last fiscal year)
Short Term Debt = 3.38m USD (from shortTermDebt, last quarter)
Debt = 182.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 15.7m
Net Debt = 119.3m USD (calculated: Debt 182.4m - CCE 63.2m)
Enterprise Value = 5.84b USD (5.72b + Debt 182.4m - CCE 63.2m)
Interest Coverage Ratio = 24.31 (Ebit TTM 220.6m / Interest Expense TTM 9.07m)
EV/FCF = 34.07x (Enterprise Value 5.84b / FCF TTM 171.4m)
FCF Yield = 2.93% (FCF TTM 171.4m / Enterprise Value 5.84b)
FCF Margin = 15.78% (FCF TTM 171.4m / Revenue TTM 1.09b)
Net Margin = 15.14% (Net Income TTM 164.4m / Revenue TTM 1.09b)
Gross Margin = 36.29% ((Revenue TTM 1.09b - Cost of Revenue TTM 691.8m) / Revenue TTM)
Gross Margin QoQ = 36.51% (prev 37.34%)
Tobins Q-Ratio = 3.46 (Enterprise Value 5.84b / Total Assets 1.69b)
Interest Expense / Debt = 4.97% (Interest Expense 9.07m / Debt 182.4m)
Taxrate = 22.59% (48.0m / 212.4m)
NOPAT = 170.7m (EBIT 220.6m * (1 - 22.59%))
Current Ratio = 2.66 (Total Current Assets 388.4m / Total Current Liabilities 145.8m)
Debt / Equity = 0.14 (Debt 182.4m / totalStockholderEquity, last quarter 1.30b)
Debt / EBITDA = 0.43 (Net Debt 119.3m / EBITDA 278.9m)
Debt / FCF = 0.70 (Net Debt 119.3m / FCF TTM 171.4m)
Total Stockholder Equity = 1.29b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.77% (Net Income 164.4m / Total Assets 1.69b)
RoE = 12.79% (Net Income TTM 164.4m / Total Stockholder Equity 1.29b)
RoCE = 15.21% (EBIT 220.6m / Capital Employed (Equity 1.29b + L.T.Debt 164.0m))
RoIC = 11.46% (NOPAT 170.7m / Invested Capital 1.49b)
WACC = 6.71% (E(5.72b)/V(5.90b) * Re(6.80%) + D(182.4m)/V(5.90b) * Rd(4.97%) * (1-Tc(0.23)))
Discount Rate = 6.80% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -68.14 | Cagr: -0.53%
[DCF] Terminal Value 76.88% ; FCFF base≈164.1m ; Y1≈181.0m ; Y5≈231.4m
[DCF] Fair Price = 107.0 (EV 3.53b - Net Debt 119.3m = Equity 3.41b / Shares 31.9m; r=8.35% [WACC [floored]]; 5y FCF grow 11.94% → 2.50% )
EPS Correlation: 98.49 | EPS CAGR: 13.41% | SUE: 2.08 | # QB: 1
Revenue Correlation: 95.93 | Revenue CAGR: 6.21% | SUE: 3.27 | # QB: 2
EPS current Quarter (2026-09-30): EPS=1.53 | Chg30d=+1.99% | Revisions=+25% | Analysts=2
EPS current Year (2026-12-31): EPS=5.83 | Chg30d=+2.47% | Revisions=+0% | GrowthEPS=+13.1% | GrowthRev=+9.1%
EPS next Year (2027-12-31): EPS=6.21 | Chg30d=+1.64% | Revisions=+25% | GrowthEPS=+6.6% | GrowthRev=+5.3%
[Analyst] Revisions Ratio: +29% (up=3, down=1)